Dimethylformamide → Rifampicin

HRID 46715

반응식

HRID 46715 반응식
[CH3:1][C:2]1[C:7]2[O:8][C@:9]3([CH3:49])[O:12][CH:13]=[CH:14][C@H:15]([O:47][CH3:48])[C@@H:16]([CH3:46])[C@@H:17]([O:42][C:43]([CH3:45])=[O:44])[C@H:18]([CH3:41])[C@H:19]([OH:40])[C@H:20]([CH3:39])[C@@H:21]([OH:38])[C@@H:22]([CH3:37])[CH:23]=[CH:24][CH:25]=[C:26]([CH3:36])[C:27]([NH:29][C:30]4[C:34](=[O:35])[C:4](=[C:5]([C:32](=[O:33])[CH:31]=4)[C:6]=2[C:10]3=[O:11])[C:3]=1[OH:50])=[O:28].[CH3:51]N(C)C=O.C(N1CN(C(C)(C)C)CN(C(C)(C)C)C1)(C)(C)C.[NH2:74][N:75]1[CH2:80][CH2:79][N:78]([CH3:81])[CH2:77][CH2:76]1>C(O)(=O)C>[CH3:1][C:2]1[C:7]2[O:8][C@:9]3([CH3:49])[O:12][CH:13]=[CH:14][C@H:15]([O:47][CH3:48])[C@@H:16]([CH3:46])[C@@H:17]([O:42][C:43]([CH3:45])=[O:44])[C@H:18]([CH3:41])[C@H:19]([OH:40])[C@H:20]([CH3:39])[C@@H:21]([OH:38])[C@@H:22]([CH3:37])[CH:23]=[CH:24][CH:25]=[C:26]([CH3:36])[C:27]([NH:29][C:30]4[C:31](/[CH:51]=[N:74]/[N:75]5[CH2:80][CH2:79][N:78]([CH3:81])[CH2:77][CH2:76]5)=[C:32]([OH:33])[C:5]([C:6]=2[C:10]3=[O:11])=[C:4]([C:34]=4[OH:35])[C:3]=1[OH:50])=[O:28]

참가 물질

6

반응물 4

HCID 6228DimethylformamideHCID 663521,3,5-Tris(1,1-dimethylethyl)hexahydro-1,3,5-triazineHCID 813491-Amino-4-methylpiperazineHCID 6436726Rifamycin S

생성물 1

HCID 135398735Rifampicin

시약·촉매·용매 1

HCID 176Acetic Acid용매

실험 절차

15 g. Rifamycin S are dissolved in 50 ml. dimethylformamide and 5.5 g. 1,3,5-tri-(tert.-butyl)-hexahydro-1,3,5-triazine are added to the solution. The reaction mixture is then kept at 75° C. for about 3 hours and 1-amino-4-methylpiperazine, acidified with acetic acid, added directly according to the procedure described in Example 1, followed by analogous working up to give substantially pure rifampicin.

후처리

  1. additionadded directly

출처 및 근거

ORD 기록
ord-1bae79cdb4cd473f92543be6b20fce4c
출처 데이터셋
uspto-grants-1979_11
특허 번호
US04174320

연결된 노트

불러오는 중…